Page 189 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Cost analysis on DPYD genotype-guided dosing
higher in DPYD variant allele carriers (€2,972) than in non-carriers (€825), p<0.0001.19
To conclude, in addition to the important finding that upfront DPYD genotype-guided dose individualization is able to markedly increase patient safety, this study now confirms that this upfront DPYD screening strategy does not result in an increase in direct medical costs. This further endorses that DPYD genotyping should be implemented as routine clinical care.
6
187